Reaction
Incision Site Pain reporting signals
As of the last recalculation, Incision Site Pain appears in 1,161 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 101.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 63 | 101.5 | 102.0 |
| Ganciclovir | 36 | 65.0 | 65.3 |
| Ganciclovir Sodium | 36 | 62.9 | 63.1 |
| Diltiazem Hydrochloride Extended-Release Tablets | 37 | 60.2 | 60.4 |
| Heparin Sodium | 31 | 41.5 | 41.6 |
| Mycophenolic Acid | 68 | 40.4 | 40.5 |
| Sodium Bicarbonate | 45 | 36.1 | 36.1 |
| Sodium Bicarbonate Injection, | 45 | 36.1 | 36.1 |
| Calcium Gluconate | 18 | 27.2 | 27.2 |
| Bupivacaine | 11 | 21.3 | 21.3 |
| Diltiazem Hydrochloride | 38 | 20.3 | 20.3 |
| Amikacin | 17 | 18.1 | 18.1 |
| Iron Sucrose | 9 | 17.0 | 17.1 |
| Micafungin Sodium | 8 | 17.0 | 17.0 |
| Magnesium Sulfate In Water For | 11 | 15.6 | 15.6 |
| Magnesium Sulfate Heptahydrate | 11 | 15.3 | 15.3 |
| Magnesium Sulfate | 11 | 15.2 | 15.3 |
| Piperacillin And Tazobactam | 8 | 11.3 | 11.3 |
| Isoniazid | 10 | 11.2 | 11.2 |
| Drospirenone And Ethinyl Estradiol | 18 | 7.4 | 7.4 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 6.3 | 6.3 |
| Risankizumab-Rzaa | 27 | 6.0 | 6.0 |
| Botulinum Toxin Type A | 4 | 5.8 | 5.8 |
| Orlistat | 8 | 5.6 | 5.6 |
| Romosozumab-Aqqg | 4 | 5.3 | 5.3 |
| Glecaprevir And Pibrentasvir | 3 | 4.9 | 4.9 |
| Etonogestrel | 11 | 4.2 | 4.2 |
| Copper | 3 | 1.2 | 1.2 |